COPD often manifests as chronic bronchitis and emphysema, typically developing from prolonged exposure to irritants like ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition impacts millions globally, with a 2023 analysis by DelveInsight reporting ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Regeneron recently secured approval for Dupixent in treating Chronic Obstructive Pulmonary Disease (COPD) in the European Union, with a pending approval decision in the United States expected in the ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Chronic obstructive pulmonary disease (COPD) has seen no new therapies ... worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the ...

With Regeneron and partner Sanofi (SNY) gaining new approvals including the big one - chronic obstructive pulmonary disease ('COPD'), I expect continued strong growth of Dupixent in 2025 and ...

Regeneron does not undertake any obligation ... In September, the FDA and Chinese regulators both approved Dupixent for patients with uncontrolled COPD and an eosinophilic phenotype.